Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
According to Tipranks, Truist told investors in a research note that it was revising estimates for YEZTUGO, a prescription drug to lower HIV-1 risk, heading into fourth-quarter earnings. The firm is also adjusting certain timelines following recent updates on upcoming launches, including BIC/LEN and Hepcludex in the United States. On the same day, Citigroup also provided an update on Gilead Sciences, Inc. (NASDAQ:GILD). The firm lifted its price target on the stock to $156 from $140, while keeping a Buy rating. Citi's adjustment came as part of the firm's broader Q4 preview of biopharmaceutical stocks. The bank expects achievable estimates and reduced policy risk to create a promising environment for the group this year. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company engaged in the development of medicines to prevent and treat various life-threatening diseases, including HIV, viral hepatitis, and cancer. While we acknowledge the potential of GILD as an inv
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results [Yahoo! Finance]Yahoo! Finance
- UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Leerink Partners from $114.00 to $146.00. They now have an "outperform" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at TD Cowen from $125.00 to $145.00. They now have a "buy" rating on the stock.MarketBeat
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 1/29/26 - Form 4
- 1/28/26 - Form 144
- 1/26/26 - Form 4
- GILD's page on the SEC website